Efficacy of quetiapine in Parkinson's patients with psychosis

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1, 2000, Pages 54-60

  Targum, Steven D ^a   Abbott, Jacob L ^a  

^a Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; HALOPERIDOL; LEVODOPA; QUETIAPINE; RISPERIDONE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DELUSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; VERTIGO; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0033955214     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002000-00010     Document Type: Article

References (25)

1. Cummings JL. Neuropsychiatric complications of drug treatment of Parkinson's disease. In: Huber SJ, Cummings JL, eds. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press; 1992:313-27.
2. Friedman A. Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 1994;89:258-61.
3. Klawans HL. Levodopa psychosis. Psychiatr Ann 1978;8:447-51.
4. Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs: characteristics, evaluation and treatment. Drugs Aging 1997;10:367-83.
5. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994;44[suppl 10]: S1-S52.
6. Doraiswamy M, Martin W, Metz A, DeVeaugh-Griss J. Psychosis in Parkinson's. disease: diagnosis and treatment. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:835-46.
7. Wagner ML, Defilippi JL, Menza MA, Sage JI. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-80.
8. Lew MF, Waters CH. Clozapine treatment in Parkinsonism with psychosis. J Am Geriatr Soc 1993;41:669-71.
9. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korzyn AD. Low dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-4.
10. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2 year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-6.
11. Meco G, Alessandria A, Bonifati V, Guistini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994;343:1370-1.
12. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56:556-9.
13. Casey DE. Seroquel (quetiapine): pre-clinical and clinical findings of a new atypical antipsychotic. Expert Opin Invest Drugs 1996; 5:939-57.
14. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of pre-clinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1995;1:50-73.
15. Juncos JL, Evatt ML, Jewatt D. Long-term effects of quetiapine fumarate in Parkinsonism complicated by psychosis. Neurology (in press).
16. McManus DQ, Arvanitis LA, Kowalcyk BB, Seroquel Trial 48 Study Group. Seroquel (quetiapine), a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999;60:292-8.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
18. CGI Clinical Global Impressions. ECDEU assessment manual for psychopharmacology, revised ed. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976;218-22.
19. AIMS. ECDEU Assessment manual for psychopharmacology, revised ed [ADM 76-338]. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976;534-5.
20. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-9.
21. Fahn S, Elton RL, UPDRS Development Committee. UPDRS -Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: MacMillan Health Care Information, 1987:153-64.
22. Hoehn MU, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
23. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994;344:681.
24. Arvanitis LA, Miller BG, Seroquel Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-16.
25. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14:283-95.